You have read all your free articles, to continue reading subscribe to read the rest of this content.
Ilya Pharma has secured a total of 5.3 million EUR in funding from the European Innovation Council (EIC) Accelerator program of blended financing. The funds will enable Ilya Pharma to accelerate a Phase II Trial of its lead drug candidate ILP100 which has the potential to heal problematic non-heaAlready a…
AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal. Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. "This agreement supports the managemeAlready a subscriber Login You have read all…
In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners. The issue was carried out during the third quarter of 2022 as…
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.Already a subscriber Login You have read all your free…
